Literature DB >> 10704355

Vaccinia virus-related events and phenotypic changes after infection of dendritic cells derived from human monocytes.

R Drillien1, D Spehner, A Bohbot, D Hanau.   

Abstract

The in vitro interactions between vaccinia virus (VV) and monocyte-derived human dendritic cells (DC) have been studied to gain a better understanding of the mechanisms involved in the induction of an immune response by VV. This work showed that VV binds to DC less efficiently than to HeLa cells (HeLa). Capping of viral antigens on the DC surface and electron microscopic examinations suggested that VV enters into DC mainly by endocytosis instead of fusion as for HeLa. Early viral-encoded proteins were expressed in DC but late viral proteins and viral DNA synthesis did not occur. Nevertheless, when successfully infected, DC expressed a similar amount of a foreign, viral-encoded protein, as HeLa, if the early component of the p7.5 promoter was used. VV infection did not lead to DC maturation as determined by following the level of several cell surface markers associated with maturation, but an inhibition of the expression of the costimulatory molecule CD80 was noticed. The proliferation of allogeneic peripheral blood lymphocytes (PBL) was stimulated by VV-infected DC or inhibited depending on the particular donor lymphocytes employed. PBL from VV-vaccinated individuals with good memory responses to VV antigens proliferated in the presence of infected autologous DC. PBL from individuals with poor memory responses to VV and one unvaccinated individual also proliferated, albeit to a lower level, in the presence of infected autologous DC. These results suggest that VV-infected DC could both stimulate memory cells and prime naive cells in vitro. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10704355     DOI: 10.1006/viro.2000.0203

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  28 in total

1.  Selective induction of host genes by MVA-B, a candidate vaccine against HIV/AIDS.

Authors:  Susana Guerra; José Manuel González; Núria Climent; Hugh Reyburn; Luis A López-Fernández; José L Nájera; Carmen E Gómez; Felipe García; José M Gatell; Teresa Gallart; Mariano Esteban
Journal:  J Virol       Date:  2010-06-09       Impact factor: 5.103

Review 2.  Viral vector-based therapeutic cancer vaccines.

Authors:  Cecilia Larocca; Jeffrey Schlom
Journal:  Cancer J       Date:  2011 Sep-Oct       Impact factor: 3.360

3.  Vaccinia virus infection induces dendritic cell maturation but inhibits antigen presentation by MHC class II.

Authors:  Yongxue Yao; Ping Li; Pratibha Singh; Allison T Thiele; David S Wilkes; Gourapura J Renukaradhya; Randy R Brutkiewicz; Jeffrey B Travers; Gary D Luker; Soon-Cheol Hong; Janice S Blum; Cheong-Hee Chang
Journal:  Cell Immunol       Date:  2007-08-02       Impact factor: 4.868

4.  Interference with SAMHD1 Restores Late Gene Expression of Modified Vaccinia Virus Ankara in Human Dendritic Cells and Abrogates Type I Interferon Expression.

Authors:  Katja Sliva; Judith Martin; Christine von Rhein; Tobias Herrmann; Anastasia Weyrich; Masako Toda; Barbara S Schnierle
Journal:  J Virol       Date:  2019-10-29       Impact factor: 5.103

5.  Differences and similarities in viral life cycle progression and host cell physiology after infection of human dendritic cells with modified vaccinia virus Ankara and vaccinia virus.

Authors:  Ann Chahroudi; David A Garber; Patrick Reeves; Luzheng Liu; Daniel Kalman; Mark B Feinberg
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

6.  A differential role for macropinocytosis in mediating entry of the two forms of vaccinia virus into dendritic cells.

Authors:  Kerrie J Sandgren; John Wilkinson; Monica Miranda-Saksena; Gerald M McInerney; Karen Byth-Wilson; Phillip J Robinson; Anthony L Cunningham
Journal:  PLoS Pathog       Date:  2010-04-22       Impact factor: 6.823

7.  Recombinant lambda-phage nanobioparticles for tumor therapy in mice models.

Authors:  Amir Ghaemi; Hoorieh Soleimanjahi; Pooria Gill; Zuhair Hassan; Soodeh Razeghi M Jahromi; Farzin Roohvand
Journal:  Genet Vaccines Ther       Date:  2010-05-12

8.  Attenuation of vaccinia virus by the expression of human Flt3 ligand.

Authors:  Kamila Zurkova; Petr Hainz; Jitka Krystofova; Luda Kutinova; Miloslav Sanda; Sarka Nemeckova
Journal:  Virol J       Date:  2010-05-26       Impact factor: 4.099

9.  Regulation of maturation and activating potential in CD8+ versus CD8- dendritic cells following in vivo infection with vaccinia virus.

Authors:  Rama D Yammani; Sharmila Pejawar-Gaddy; Thaddeus C Gurley; Eric T Weimer; Elizabeth M Hiltbold; Martha A Alexander-Miller
Journal:  Virology       Date:  2008-06-30       Impact factor: 3.616

10.  Regulating cytokine function enhances safety and activity of genetic cancer therapies.

Authors:  Hannah Chen; Padma Sampath; Weizhou Hou; Stephen H Thorne
Journal:  Mol Ther       Date:  2012-11-13       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.